What is the SARS-CoV-2 Re-Infection Rate in the General Population?
BACKGROUND AND PURPOSE:
Qureshi et al. (Clinical Infectious Diseases, 2021) determined the rate of SARS-CoV-2 re-infection, associated factors, and the mortality rate in patients with previous SARS-CoV-2 infection
Presence of SARS-CoV-2 infection
Patients who received serial tests between December 2019 and November 2020
Re-infection: 2 positive tests separated by an interval of >90 days after resolution of first infection
Resolution of infection: ≥2 consecutive negative tests
Logistic regression used to analyze covariates, including demographic and clinical characteristics
0.7% (95% CI, 0.5 to 0.9%); n=63
Mean period between two positive tests
116 (SD 21) days
Factors associated with re-infection
Odds ratio (OR) 1.9 (95% CI, 1.1 to 3.2)
Nicotine dependence/tobacco use
OR 2.7 (95% CI, 1.6 to 4.5)
Compared to the primary infection, these patients’ re-infections had a lower rate of
Acute kidney injury
3.2% (2 deaths)
In this large cohort of patients with a previous SARS-CoV-2 infection, re-infection occurred at low rate (0.7%)
The secondary infection was associated with milder disease, though there was associated mortality
The authors state
Our observations strongly suggest that survivors from SARS-CoV-2 infection must not relax compliance with proven interventions in prevention of SARS-CoV-2 transmission such as social distancing and universal face mask use
OBG Project CME requires a modern web browser (Internet Explorer 10+, Mozilla Firefox, Apple Safari, Google Chrome, Microsoft Edge). Certain educational activities may require additional software to view multimedia, presentation, or printable versions of their content. These activities will be marked as such and will provide links to the required software. That software may be: Adobe Flash, Apple QuickTime, Adobe Acrobat, Microsoft PowerPoint, Windows Media Player, or Real Networks Real One Player.
Disclosure of Unlabeled Use
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications.
The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information
presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.
Jointly provided by
NOT ENOUGH CME HOURS
It appears you don't have enough CME Hours to take this Post-Test. Feel free to buy additional CME hours or upgrade your current CME subscription plan